SkylineDx at the forefront of a genomic revolution
SkylineDx is dedicated to optimize therapeutic decision making through the development of molecular diagnostic tests for blood cancers and thereby improving the quality of life of blood cancer patients.
Discover more
Learn more about MMprofiler™, the lead product of SkylineDx. It is a prognostic test to determine the level of risk of a multiple myeloma patient by classifying such patient into a “high” or “standard” risk group with the use of the novel SKY92 gene signature.
Learn moreLatest news
13 Jun 2018
SkylineDx Poster Presentations at EHA Meeting Further Validate Use of MMprofilerTM with SKY92 in Multiple Myeloma
SkylineDx Poster Presentations at EHA Meeting Further Validate Use of MMprofilerTM with SKY92 in Multiple Myeloma SKY92 risk stratification at relapse provides additional prognostic information for standardrisk Multiple Myeloma patients ...
Upcoming Events
14 Jun 2018 - 17 Jun 2018, Stockholmsmässan Congress Center, Stockholm, Sweden
23rd Congress of the European Hematology Association (EHA)
15 Aug 2018 - 18 Aug 2018, Sydney, Australia
World Congress on the Cancers of the Skin
12 Sep 2018 - 15 Sep 2018, Hilton Americas, Houston Texas, USA
Society of Hematologic Oncology (SOHO) Annual Meeting